EOG Resources Inc vs Twist Bioscience Corp — how do they compare? EOG Resources Inc trades at $149.22 (market cap $77.90B), while Twist Bioscience Corp trades at $163.21 (market cap $10.08B). The key difference: EOG Resources Inc is far larger — about 7.7× Twist Bioscience Corp's market cap, and EOG Resources Inc pays a 2.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Twist Bioscience Corp for 27 Days on average.
| EOG | TWST | |
|---|---|---|
Market Cap | $77.90B | $10.08B |
Volume | 2,930,386 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $153.74 | $205.00 |
52-Week Low | $101.78 | $25.45 |
Typical Hold Time | 59 Days | 27 Days |
Enterprise Value | $81.24B | $10.01B |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $149.40, up 3.6% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios appear attractive, including a P/E of 11.56 and EV/EBITDA of 5.84. Recent news highlights robust operational execution and disciplined capital allocation, with the company announcing a CFO transition and scheduling its Q3 2026 earnings call for November 6.
The outlook for EOG remains positive, supported by strong profitability metrics, a solid balance sheet, and a unanimous analyst buy/hold consensus with no sell ratings. Key opportunities include projected revenue growth to $26.6B in 2026 and a 5% oil volume growth target. Risks involve exposure to volatile oil prices, as seen in recent price retreats impacting energy stocks, and potential execution challenges amid macroeconomic uncertainty. The stock offers value with a consensus price target of $164.77, implying ~10% upside.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →